MedSiLa is a four-stage pipeline that turns patient-reported symptoms and clinical data into causality-adjudicated, actionable alerts.
Structured electronic patient-reported outcomes (ePRO) capture symptoms as they happen, not weeks later at the next visit.
Symptom data is enriched with the patient's full medication record through FHIR and SMART on FHIR integration, pulling in concurrent therapies, dosing, and timing directly from the EHR.
A causality-gated fusion engine evaluates each symptom against known drug-drug interaction pathways (CYP450, QTc), polypharmacy burden (Drug Burden Index), and adjudicated causality using established clinical frameworks (WHO-UMC, Naranjo, Liverpool, DIPS). Similar historical cases are retrieved to support the assessment.
Alerts are tiered and gated: immediate alert, hold-and-re-evaluate, or suppress-and-log, so care teams see what matters when it matters, without alert fatigue. Every output is informational, designed to support clinical judgment rather than replace it.
MedSiLa's reasoning layer is grounded in the same frameworks clinicians already trust:
The core mechanism, a causality-gated fusion of interaction signals, polypharmacy burden, and patient context, is the subject of a pending patent application.
MedSiLa integrates into existing EHR workflows rather than asking care teams to adopt a new system. Outputs are designed to be reviewable and informational, keeping clinical decision-making where it belongs, with the care team.
We are currently working with early pilot partners to validate the platform in live oncology settings.
No new system to adopt — MedSiLa integrates via FHIR and SMART on FHIR.
Every output is informational, keeping clinical judgment with the care team.
Validated in live oncology settings alongside early pilot partners.